The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Research Grant, 2022Objectively Measuring the Severity of Vocal and Speech-related Symptoms Associated with Parkinson’s Disease
Study Rationale: The ability to objectively measure vocal symptoms is necessary to better characterize the emergence and development of speech deficits, particularly in the early phases of Parkinson’s...
-
2022: Accelerated Therapeutics Program, 2022Using Small Molecules that Modulate Mitochondrial Function for the Treatment of Parkinson's Disease
Study Rationale: Dysfunction in energy-producing structures called mitochondria is a crucial driver of the initiation and progression of Parkinson’s disease (PD). Mitochondria in the cells of people...
-
Fall 2021 RFP: Accelerating Early Proof-of-Concept Testing of Promising PD Therapies, 2022Assessment of Alpha-synuclein Aggregation Inhibitor ASN121151 as a Potential New Treatment for Parkinson’s Disease
Study Rationale: Genetic defects in the gene encoding alpha-synuclein cause the protein to aggregate in the brains of people with a familial form of Parkinson’s disease (PD). We have developed a novel...
-
Alpha-synuclein Seed Amplification Assay Program, 2022Maximizing the Sensitivity of Seed Amplification Assays Used to Detect Alpha-synuclein Aggregates
Study Rationale: One characteristic of Parkinson’s disease (PD) is the aggregation of proteins such as alpha-synuclein in the brain. To diagnose PD, it is important to be able to detect such...
-
Diversity, Equity and Inclusivity in Parkinson's research, 2022Overcoming Inequity in the Treatment of Parkinson’s Disease: Recognizing and Caring for Underserved Communities in Brazil
Study Rationale: Brazil has enormous economic and social inequalities. Pesticides, heavy metals and other pollutants can contribute to the development of degenerative conditions such as Parkinson's...
-
2022: Accelerated Therapeutics Program, 2022Translation of the Neuroprotective Immune Modulator LBT-3627 into First-In-Human Studies
Study Rationale: LBT-3627 is a disease-modifying therapeutic candidate that has been shown to reduce brain inflammation and immune imbalance in preclinical models of Parkinson's disease (PD). A recent...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.